News
ESMO: Ivonescimab beats BeOne PD-1 in first-line lung cancer
Akeso/Summit's PD-1xVEGF drug ivonescimab bests a PD-1 inhibitor as first-line therapy in Chinese NSCLC patients, but a bigger test is yet to come.
Saturday 7 February 2026
